 Jennifer Barker
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Addison Disease | 6 | 2012 | 43 | 1.470 |
Why?
| | Diabetes Mellitus, Type 1 | 21 | 2012 | 3697 | 1.370 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2025 | 37 | 1.290 |
Why?
| | Autoantibodies | 15 | 2012 | 1498 | 1.070 |
Why?
| | Autoimmune Diseases | 6 | 2011 | 459 | 0.900 |
Why?
| | Endocrinology | 1 | 2023 | 79 | 0.800 |
Why?
| | Steroid 21-Hydroxylase | 4 | 2012 | 30 | 0.740 |
Why?
| | Endocrine System Diseases | 2 | 2015 | 35 | 0.700 |
Why?
| | Anorexia Nervosa | 1 | 2021 | 86 | 0.650 |
Why?
| | Neonatal Screening | 2 | 2025 | 170 | 0.560 |
Why?
| | Metabolic Diseases | 2 | 2015 | 108 | 0.510 |
Why?
| | Celiac Disease | 4 | 2008 | 291 | 0.470 |
Why?
| | Physicians | 1 | 2023 | 902 | 0.460 |
Why?
| | Emergencies | 1 | 2015 | 164 | 0.440 |
Why?
| | Internship and Residency | 1 | 2023 | 1131 | 0.420 |
Why?
| | Child | 21 | 2025 | 21896 | 0.360 |
Why?
| | Turner Syndrome | 2 | 2022 | 53 | 0.360 |
Why?
| | Disease Management | 1 | 2015 | 624 | 0.350 |
Why?
| | Insulin Antibodies | 2 | 2009 | 105 | 0.340 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2009 | 203 | 0.340 |
Why?
| | HLA-D Antigens | 1 | 2008 | 34 | 0.300 |
Why?
| | HLA-DQ Antigens | 5 | 2009 | 181 | 0.280 |
Why?
| | Hypoglycemia | 1 | 2012 | 442 | 0.270 |
Why?
| | Polymorphism, Genetic | 2 | 2009 | 652 | 0.270 |
Why?
| | Sweetening Agents | 1 | 2007 | 53 | 0.260 |
Why?
| | Insulin-Secreting Cells | 2 | 2008 | 372 | 0.260 |
Why?
| | Preventive Medicine | 1 | 2006 | 43 | 0.250 |
Why?
| | Humans | 37 | 2025 | 136899 | 0.250 |
Why?
| | Primary Prevention | 1 | 2007 | 195 | 0.240 |
Why?
| | Mineralocorticoids | 1 | 2025 | 8 | 0.230 |
Why?
| | Dentate Gyrus | 1 | 2025 | 38 | 0.230 |
Why?
| | Autoimmunity | 5 | 2010 | 893 | 0.230 |
Why?
| | HLA-DR Antigens | 4 | 2009 | 228 | 0.220 |
Why?
| | Disease Progression | 5 | 2012 | 2744 | 0.210 |
Why?
| | HLA-DR3 Antigen | 3 | 2010 | 80 | 0.210 |
Why?
| | Metabolic Syndrome | 1 | 2007 | 348 | 0.200 |
Why?
| | Infant, Newborn | 5 | 2025 | 6043 | 0.200 |
Why?
| | Patient Care | 1 | 2023 | 110 | 0.200 |
Why?
| | Tetany | 1 | 2002 | 2 | 0.200 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 2175 | 0.200 |
Why?
| | Parental Leave | 1 | 2022 | 26 | 0.200 |
Why?
| | Prediabetic State | 2 | 2009 | 247 | 0.190 |
Why?
| | Education, Medical, Graduate | 2 | 2023 | 476 | 0.190 |
Why?
| | Child, Preschool | 8 | 2025 | 11013 | 0.190 |
Why?
| | Insulin | 3 | 2008 | 2389 | 0.190 |
Why?
| | Adolescent | 13 | 2022 | 21402 | 0.190 |
Why?
| | Interferon-alpha | 3 | 2009 | 198 | 0.190 |
Why?
| | Mass Screening | 3 | 2012 | 1262 | 0.190 |
Why?
| | Glucose | 1 | 2007 | 1018 | 0.180 |
Why?
| | Biomarkers | 2 | 2012 | 4148 | 0.180 |
Why?
| | Testosterone | 1 | 2025 | 398 | 0.180 |
Why?
| | Monosomy | 1 | 2021 | 12 | 0.180 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 38 | 0.170 |
Why?
| | Genotype | 5 | 2011 | 1906 | 0.170 |
Why?
| | Sex Chromosome Aberrations | 1 | 2021 | 67 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2025 | 596 | 0.170 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2011 | 18 | 0.160 |
Why?
| | Liver Diseases | 1 | 2022 | 311 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 302 | 0.150 |
Why?
| | Islets of Langerhans | 5 | 2009 | 803 | 0.150 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 142 | 0.150 |
Why?
| | Male | 14 | 2025 | 67308 | 0.150 |
Why?
| | Female | 15 | 2025 | 72703 | 0.140 |
Why?
| | Risk Factors | 6 | 2012 | 10313 | 0.140 |
Why?
| | Blood Glucose | 2 | 2009 | 2161 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 5 | 2011 | 2416 | 0.140 |
Why?
| | Glucose Tolerance Test | 3 | 2009 | 353 | 0.140 |
Why?
| | Hydrocortisone | 2 | 2012 | 317 | 0.130 |
Why?
| | HLA-DR4 Antigen | 2 | 2008 | 78 | 0.130 |
Why?
| | Neurons | 1 | 2025 | 1608 | 0.120 |
Why?
| | Infant | 4 | 2025 | 9408 | 0.120 |
Why?
| | Time Factors | 4 | 2012 | 6802 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2012 | 2030 | 0.110 |
Why?
| | Administration, Oral | 2 | 2007 | 811 | 0.110 |
Why?
| | Morbidity | 1 | 2015 | 321 | 0.110 |
Why?
| | Hospitalization | 1 | 2004 | 2183 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2012 | 5126 | 0.110 |
Why?
| | Genetic Testing | 2 | 2006 | 453 | 0.100 |
Why?
| | Renin | 1 | 2012 | 34 | 0.100 |
Why?
| | Proportional Hazards Models | 2 | 2007 | 1262 | 0.100 |
Why?
| | Haplotypes | 3 | 2011 | 487 | 0.100 |
Why?
| | Global Health | 1 | 2015 | 384 | 0.100 |
Why?
| | HLA-B Antigens | 1 | 2011 | 62 | 0.090 |
Why?
| | Gene Frequency | 2 | 2010 | 521 | 0.090 |
Why?
| | Endocrine Cells | 1 | 2010 | 7 | 0.090 |
Why?
| | Potassium Channels | 1 | 2011 | 153 | 0.090 |
Why?
| | Prognosis | 2 | 2012 | 4011 | 0.080 |
Why?
| | Alleles | 2 | 2011 | 888 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | Models, Biological | 2 | 2008 | 1774 | 0.080 |
Why?
| | HLA-DQ beta-Chains | 1 | 2009 | 63 | 0.080 |
Why?
| | Graves Disease | 1 | 2009 | 34 | 0.080 |
Why?
| | Homozygote | 1 | 2009 | 203 | 0.080 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 112 | 0.080 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 168 | 0.080 |
Why?
| | Antibody Specificity | 2 | 2007 | 189 | 0.070 |
Why?
| | Fluoroimmunoassay | 1 | 2007 | 3 | 0.070 |
Why?
| | Diet, Gluten-Free | 1 | 2008 | 43 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 107 | 0.070 |
Why?
| | Transglutaminases | 1 | 2008 | 156 | 0.070 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2006 | 54 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1061 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2008 | 208 | 0.060 |
Why?
| | Adrenal Gland Diseases | 1 | 2006 | 6 | 0.060 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2006 | 15 | 0.060 |
Why?
| | Testosterone Propionate | 1 | 2025 | 1 | 0.060 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 28 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2005 | 27 | 0.060 |
Why?
| | Dihydrotestosterone | 1 | 2025 | 44 | 0.060 |
Why?
| | Autoantigens | 1 | 2008 | 429 | 0.060 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 126 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 14 | 0.060 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 48 | 0.060 |
Why?
| | Organ Specificity | 1 | 2005 | 304 | 0.060 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2004 | 63 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2004 | 117 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2008 | 344 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 1945 | 0.050 |
Why?
| | Glutamate Decarboxylase | 1 | 2004 | 170 | 0.050 |
Why?
| | Biological Evolution | 1 | 2008 | 466 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 288 | 0.050 |
Why?
| | HLA Antigens | 1 | 2005 | 237 | 0.050 |
Why?
| | Neurogenesis | 1 | 2025 | 149 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 168 | 0.050 |
Why?
| | Cohort Studies | 2 | 2022 | 5711 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2005 | 362 | 0.050 |
Why?
| | Animals | 5 | 2025 | 36915 | 0.050 |
Why?
| | Cell Survival | 1 | 2025 | 1122 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 1037 | 0.050 |
Why?
| | Estradiol | 1 | 2025 | 513 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2007 | 3282 | 0.050 |
Why?
| | Karyotype | 1 | 2021 | 18 | 0.040 |
Why?
| | Chromosomes, Human, Y | 1 | 2021 | 23 | 0.040 |
Why?
| | Genitalia | 1 | 2021 | 30 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1033 | 0.040 |
Why?
| | Mosaicism | 1 | 2021 | 73 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1695 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 319 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 316 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2025 | 2500 | 0.040 |
Why?
| | Bone and Bones | 1 | 2002 | 317 | 0.040 |
Why?
| | Proteins | 1 | 2004 | 1012 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 5398 | 0.040 |
Why?
| | Young Adult | 2 | 2012 | 13157 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1282 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2709 | 0.040 |
Why?
| | Patient Compliance | 1 | 2002 | 586 | 0.040 |
Why?
| | Pedigree | 2 | 2010 | 509 | 0.030 |
Why?
| | Phenotype | 2 | 2021 | 3201 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5675 | 0.030 |
Why?
| | Mice | 3 | 2008 | 17775 | 0.030 |
Why?
| | Prospective Studies | 2 | 2006 | 7543 | 0.030 |
Why?
| | Reference Values | 2 | 2009 | 820 | 0.030 |
Why?
| | Adult | 5 | 2011 | 37595 | 0.030 |
Why?
| | Colorado | 1 | 2004 | 4491 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1361 | 0.030 |
Why?
| | HLA-B15 Antigen | 1 | 2011 | 13 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 88 | 0.020 |
Why?
| | HLA-B8 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 359 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 172 | 0.020 |
Why?
| | Middle Aged | 3 | 2009 | 33118 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5730 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 11 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 20 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 268 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2004 | 10768 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 239 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 54 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 401 | 0.020 |
Why?
| | Europium | 1 | 2007 | 2 | 0.020 |
Why?
| | Fluorometry | 1 | 2007 | 17 | 0.020 |
Why?
| | Luminescent Agents | 1 | 2007 | 7 | 0.020 |
Why?
| | Risk | 1 | 2010 | 905 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 182 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 54 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2008 | 601 | 0.020 |
Why?
| | United States | 1 | 2022 | 14595 | 0.010 |
Why?
| | Aged | 1 | 2004 | 23641 | 0.010 |
Why?
| | Lung Diseases | 1 | 2011 | 768 | 0.010 |
Why?
| | Family | 1 | 2009 | 667 | 0.010 |
Why?
| | Family Health | 1 | 2005 | 200 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 640 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1460 | 0.010 |
Why?
| | Survival Rate | 1 | 2006 | 1972 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 849 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1773 | 0.010 |
Why?
|
|
Barker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|